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Abstract—It is well known that 40%–50% of hepatocellular
carcinoma (HCC) do not show increased 18F-fluorodeoxyglucose
(FDG) uptake. Recent research studies have demonstrated that
11C-acetate may be a complementary tracer to FDG in positron
emission tomography (PET) imaging of HCC in the liver. Quanti-
tative dynamic modeling is, therefore, conducted to evaluate the
kinetic characteristics of this tracer in HCC and nontumor liver
tissue. A three-compartment model consisting of four parameters
with dual inputs is proposed and compared with that of five pa-
rameters. Twelve regions of dynamic datasets of the liver extracted
from six patients are used to test the models. Estimation of the
adequacy of these models is based on Akaike Information Criteria
(AIC) and Schwarz Criteria (SC) by statistical study. The forward
clearance K = K1 k3 (k2 + k3) is estimated and defined as
a new parameter called the local hepatic metabolic rate-constant
of acetate (LHMRAct) using both the weighted nonlinear least
squares (NLS) and the linear Patlak methods. Preliminary results
show that the LHMRAct of the HCC is significantly higher than
that of the nontumor liver tissue. These model parameters provide
quantitative evidence and understanding on the kinetic basis of
11C-acetate for its potential role in the imaging of HCC using PET.
Index Terms—local hepatic metabolic rate-constant of acetate
(LHMRAct), modeling, parameter estimation, positron emission
tomography (PET), 11C-acetate.
I. INTRODUCTION
THE hallmark of positron emission tomography (PET)is its ability to quantify in vivo the physiological and
biochemical processes in humans using intravascularly injected
PET tracers. Kinetic modeling using F-fluorodeoxyglucose
(FDG) is well established for measurements of many phys-
iological parameters, but little attention has been given to
the quantitative evaluation of liver metabolism, in spite of its
central role as the “power house” of the human body. The use
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of PET for the studying of liver disease has been mostly in
the detection of liver tumors [1]. Hepatocellular carcinoma
(HCC) is the seventh most common malignancy worldwide in
men and the ninth in women. Its occurrence is much higher
in the Asian and African. It is one of the top three causes of
cancer death in many Asian localities including China, Taiwan,
Singapore and Japan. The disease is also believed to be in an
upward trend in America due to the increasing frequency of
hepatitis C viral infection [2] and it is also a common cause of
cancer deaths among Asian immigrants. Most cases of HCC
are discovered late and less than 10% are cured with surgical
resection. Overall 5-year survival rate is less than 5% [3], [4].
The rate of glucose metabolism (glycolysis) is increased
in many forms of malignant tumors. It is directly correlated
with tumor proliferation. The investigation of tumor kinetics
by FDG-PET imaging has recently suggested that HCC has a
nonzero dephosphorylation kinetic constant [5]. A nonzero
is due to the presence of the enzyme glucose-6-phosphatase
in HCC, the abundance of which leads to leakage of the trapped
FDG metabolite back to the circulation. This may account for
one of the reasons that 40%–50% of HCC are not FDG-avid.
This is regarded as the Achilles’ heel of FDG-PET in the
evaluation of liver tumors and is clearly not acceptable in
countries where this tumor is one of the top three causes of
cancer deaths.
Recently, we have investigated the usefulness of C-acetate
in imaging HCC and other liver masses. Preliminary research
findings have suggested that this agent might have a great po-
tential role as a complementary tracer to and perhaps a better
tracer than FDG [6], [7]. Fig. 1 demonstrates a case of recurrent
HCC in the left lobe of liver after right lobectomy. CT shows
hypervascularity within the tumor. FDG-PET imaging shows no
abnormal FDG uptake by the tumor, whereas C-acetate PET
imaging shows increased metabolism.
C-acetate is a common tracer for the investigation of re-
gional myocardial oxidative metabolism [8], [9]. However, no
data exist in the literature regarding the investigation of C-ac-
etate on HCC. The exact metabolic pathway of C-acetate
within tumors such as HCC is not well understood, although
participation through acetyl-CoA in Beta oxidation for free
fatty acid synthesis is thought to be the preferred biochemical
method of incorporation. Application of kinetic modeling
techniques may in addition provide improved understanding
of these complex biokinetic processes [10]. In this research,
a three-compartment four-parameter (4-P) kinetic model with
dual inputs for evaluation of C-acetate metabolism in liver is
proposed. Comparison of this 4-P model and a three-compart-
ment five-parameter (5-P) model with dual inputs is conducted.
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Fig. 1. CT demonstrates a hypervascular lesion in the L lobe of liver (status post R lobectomy for HCC); FDG imaging shows no abnormal FDG uptake;
C-acetate imaging shows increased metabolism.
A new physiological parameter called “local hepatic metabolic
rate-constant of acetate (LHMRAct)” is introduced to charac-
terize the regional consumption of acetate by both tumor and
nontumor tissue of the liver.
II. METHODS
A. PET Scanning
An ECAT-EXACT 47 PET scanner (CTI/Siemens, Inc., TN)
is used for transaxial (septa-extended) dynamic image acquisi-
tion. Full sets of dynamic data in one single position, covering
the liver dome and apical half of the left ventricle (LV) to the
inferior part of liver, are obtained for 10 min immediately fol-
lowing bolus IV injection of C-acetate. Sampling acquisition
sequence is as follows: 4-s frames 10, 10-s frames 8, 30-s
frames 2; 60-s frames 3 and 120-s frames 2, a total of 25
frames. Standard static PET imaging covering the entire liver
is also performed from 10–20 min. Then FDG is injected and
FDG-PET imaging is performed 1 h later (allowing more than
4 half-life decay for C-acetate).
B. Human Studies
Six patients, all are hepatitis B carriers, including two with
HCC, were recruited into the study. Twelve regions of dynamic
datasets, two from HCC regions, were extracted.
C. Blood Time-Activity Dual Input Functions
The tracer time-activity curve in blood (BTAC) is used
as the input function in the kinetic model. BTAC is usually rep-
resented by a sequence of arterial or arterialized blood samples.
However, blood sampling is in general very invasive and re-
quires extra personnel and processing time. Several noninvasive
techniques have been proposed. One is proposed to extract the
input function together with the physiological parameters from
the brain dynamic images [11]. Chen, et al. [12] has reported
using the TAC obtained from the region of interest (ROI) drawn
on the target organ during dynamic PET imaging as an input
function. The utilization of image-derived input function has
been more commonly used in quantitative PET studies of the
heart [13]. The reliability of using BTAC obtained directly by
drawing a ROI over the LV or the left arterial region are inves-
tigated in [14]. Double modeling approach for dynamic cardiac
studies with PET to estimate physiological parameter is also
proposed [15].
The liver has a dual source of blood supply, receiving
oxygenated blood from the common left and right hepatic
arteries (HAs) and nutrient-rich blood via the portal vein (PV)
[16]. Therefore, the use of arterial input may, however, introduce
systematic errors in the estimated kinetic parameters because
of the ignorance of the hepatic dual blood supply from the HA
and the PV to the liver [1]. It is highly invasive and virtually
impossible in clinical settings to count the radioactivity of the
portal venous blood by direct catheterization and sampling.
For the modeling method, the existence of dual blood supply
in the liver would necessitate twice the number of parameters
required for full characterization. For preliminary investigation,
this method of modeling appears impractical. Therefore, image-
derived BTAC appears to be the only option at the moment.
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Fig. 2. Typical HA, PV and weighted dual-input function of the nontumor tissue. Solid line marked by asterisk stands for HA, triangle for the PV and square for
the weighted dual-input. The greatest activity difference among these 3 curves is during the initial radionuclide angiographic phase.
In this work, the BTAC is obtained directly from PET images
measurements. To reduce the scattering effect of radioactivity
from the adjacent tissue, the contribution from the HA is
approximated by evaluating the activity-time curve of the
abdominal aorta adjacent to the liver instead of the LV. The
contribution from the PV is evaluated by direct activity-time
measurement. The tracer arriving at the PV is delayed and
dispersed when compared with that of the HA, making its
activity similar to that of the tracer in the nontumor liver
tissue. Therefore, it is difficult to differentiate the PV from
the surrounding hepatic parenchyma. However, its location may
still be identified by its invariable anatomical position being
posterior to the pancreatic head that shows the most intense
physiological uptake of C-acetate, or by direct reference to
the CT images. The radioactivity spillover from the surrounding
tissue to the PV is significant, especially at the later part of the
study when the tracer concentration in tissue is much higher
than that in the PV. Munk et al. [1] suggested that the difference
between the two blood TACs was most pronounced around the
peak and immediately after the bolus injection. After some time
they are virtually identical. Therefore, the last five measurements
of the TACs of the PV from PET imaging are replaced by
the HA data in this study. To strike a reasonable statistical
balance without compromising physiological requirement, the
BTAC is measured empirically by using fixed weights from
these two blood supply inputs, viz. 20% contribution from HA
and 80% from PV according to their approximate percentage
perfusion to the nontumor liver tissue. Thus, the dual-input
function is calculated according to
% % (1)
where is the tracer concentration in the HA and
is the tracer concentration in the PV. However, the majority
of the blood supply to the tumor is from the HA rather than
the PV, accordingly, the weights of tumor used in this paper
is 80% contribution from HA and 20% from PV or 100%
contribution from HA. Fig. 2 shows an example of typical
blood TACs from the HA, the PV and the weighted dual-input
function for the nontumor tissue.
In this preliminary study, the metabolites of C-acetate in
blood are not taken into consideration in order not to complicate
the issue of defining the “suitable” model. Also no correction is
made for the noise scatters of the inputs.
D. Liver Kinetic Model for C-Acetate
It is not just a clinical observation that HCC may display
variable tumor kinetics. Early research on rat hepatomas had
suggested that the patterns of glycolytic enzymes might reflect
hepatoma cell growth, function, and graded dedifferentiation
[17]. Preliminary study shows that in some cases, FDG and
C-acetate are taken up by different parts of the tumor,
suggesting that mixed pathology with dual tracer kinetics could
exist within these tumors. Past researches on PET tracer kinetic
modeling have been reported [18]–[20], but there is no data
on kinetic modeling of C-acetate PET imaging in the liver.
Acetate is enzymatically converted into acetyl-CoA in the liver
[21], and then enters the Kreb’s Cycle. In the liver, the role
of Kreb’s Cycle is more complex than in heart muscles [21].
Although the exact biochemical mechanism of C-acetate
accumulation within HCC is not completely defined, there is
evidence that acetate is channeled to acetyl-CoA for fatty acid
(lipid) synthesis in tumor cells, instead of being metabolized to
CO through the Kreb’s cycle [22]. It is, therefore, reasonable
to assume that only one compartment is needed for all of the
metabolites in the liver/tumor tissue. A three-compartment
model, as shown in Fig. 3, is proposed in this study. The left
compartment of this model represents the intravascular C-ac-
etate concentration. The center compartment represents the
intracellular C-acetate concentration. The right compartment
represents the intracellular products/metabolites converted
from C-acetate (acetyl-CoA, and metabolites of fatty acid
synthesis). represents the first order rate constant for the
transport of C-acetate from blood to tissue, for reverse
transport of C-acetate from tissue to blood, for conversion
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Fig. 3. Three-compartment liver kinetic model for C-acetate.
of C-acetate to its products/metabolites, and for back
conversion from the products/metabolites to C-acetate. It
should be noted that although the real biological system is
complex, this compartmental approach, nonetheless, represents
a rather reasonable estimation for global physiological function
[10]. Since the number of compartments of this proposed
C-acetate liver model is the same as that of the FDG model
originally proposed by Sokoloff et al. [18] and further extended
by Huang et al. [19] and Phelps et al. [20], the differential
equations to the C-acetate liver 5-P model share the same
form as the FDG model
(2)
(3)
(4)
where is the C-acetate concentration in whole blood,
is the free C-acetate concentration in intracellular space,
is the intracellular products/metabolites concentration,
and is the sum of and . The solution of
in terms of macroparameters is
(5)
where
and are the macroparameters in the model [11]
and denotes the operation of temporal convolution. If
approaches zero, for simplicity, letting be zero, thus the
macroparameters of the 4-P model are given by
(6)
Regions of interest (ROIs) are drawn at 75% threshold of
maximal pixel count around the margin of the liver tumor au-
tomatically by the supplied scanner software. The same ROI is
used to measure the activity of nontumor liver tissue. TACs are
thus generated.
The total activity of tracer in tissue includes both the activity
of hepatic parenchyma and the activity within vascular/sinus
space of liver tissue. As the blood volume in the liver is fairly
large, a hepatic blood volume (HBV) term is included in our
proposed C-acetate model to account for this effect. The ob-
served total tissue activity , is
(7)
With the measurements of both BTAC and TTAC
, the rate constants to and HBV are estimated by
the weighted nonlinear least square (NLS) methods.
E. Statistical Study
The weighted NLS algorithms are used to numerically eval-
uate all the individual parameters. Statistical analysis, including
standard deviation (SD) and coefficient of variation (CV), is per-
formed. The CV of a parameter estimate is calculated from
% (8)
where is the parameter estimate and is the SD of
[11]. Model parameters are estimated by minimizing the
weighted residual sum of squares (WRSS) [1]. In our research,
the weights are proportional to the frame duration divided by
the concentration value of that time point. We assume that the
data variances are known up to a constant. Three-compartment
4-P and 5-P models are used to fit the clinical data. The best
model fitted to the data is not necessarily the model producing
the smallest WRSS, because adding more parameters generally
decreases the WRSS [1]. The Akaike Information Criteria
(AIC) [23] and Schwarz Criteria (SC) [24] are used to test
which one is the best. The AIC and the SC are given by (in the
case that the data variances are known up to a constant)
(9)
(10)
where P is the number of parameters in the model, and N is the
number of data points. The best model by the AIC or SC is the
one that minimizes the AIC or SC, respectively. The AIC or SC
provides a balance between data fitting precision in the first term
and minimum dimensionality in the second [23], [24].
F. Model Estimation of the LHMRAct
The newly proposed physiological parameter LHMRAct is
calculated using the following formula:
(11)
where to can be derived from the results of NLS fitting.
When is assumed to be zero, Patlak analysis [25] can also
be applied to this study. The ratio of and can be
calculated by
(12)
where
The data points within the period 2.5–10 min are chosen to
estimate the LHMRAct using Patlak method. The fitting results
are compared with those obtained from the NLS methods by
correlation analysis.
III. RESULTS AND CONCLUSION
Both the weighted NLS algorithms and the linear Patlak
analysis are used. The C-acetate clinical data from twelve
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TABLE I
RESULTS OF THE THREE-COMPARTMENT 4-P MODEL WITH DUAL INPUTS FOR LIVER USING C-ACETATE
TABLE II
RESULTS OF THE THREE-COMPARTMENT 5-P MODEL WITH DUAL INPUTS FOR LIVER USING C-ACETATE
ROIs are analyzed to test the 4-P and 5-P models and several
statistical criteria are used to validate their adequacy. Results
are given as the estimated value SD. The parameter esti-
mations by the weighted NLS algorithms are summarized in
Tables I and II. The model fitted curves according to the 4-P
and 5-P models for two randomly chosen datasets are shown
in Fig. 4. As seen in Tables I and II, the estimated values
of the parameters for the two models are quite close to each
other, but the CVs of the estimated parameters for the 4-P
model are far smaller than those for the 5-P model. For the
5-P model, the CVs of the estimated range from 10.7% to
38.0% except region 6 (where CV of %) and region
12 (where CV of %). The CVs of the estimated
range from 23.2% to 86.2% except region 6 (where CV of
%) and region 12 (where CV of %). Only
7 CVs of the estimated among the 12 sets of data are under
100% and the CVs of the estimated are far from acceptable.
The CVs of the estimated HBV vary greatly according to the
estimated values themselves. For the HBV whose estimated
values are under or around 0.05, the CVs vary from 51.3% to
92.8%. For the other HBV values, the CVs range from 3.4%
to 29.7%. Since the estimated values are very small and
are less reliable for interpretation, it is reasonable to assume
to be zero during the first 10-min dynamic scan. For the
4-P model, the CVs of the estimated are all less than 10%
except region 8 (where CV of %). The CVs of the
estimated range from 10.9% to 25.2% except region 12
(where CV of %). The CVs of the estimated
range from 15.4% to 72.6%. The CVs of the estimated HBV
values show no significant difference from those estimated by
the 5-P model. For those estimated values under or around
0.05, the CVs range from 42.9% to 70.0%. For the remaining
ROIs’, the CVs range from 3.3% to 25.2%. Since the vascularity
of cirrhotic liver is heterogeneous, the estimated HBV values
also exhibit moderate variability. The 4-P model is statistically
better than the 5-P model. Though the values of the WRSS for
the 4-P model are slightly larger than those for the 5-P model,
the CVs, the AICs and SCs for the 4-P model are all less than
those of the 5-P model, suggesting that the 4-P model is the best
model to characterize the kinetics of C-acetate in the liver.
Moreover, the fitting results of the 4-P model are less affected
by the initial values whereas those of 5-P model were greatly
affected. Table III shows the results of the estimated LHMRAct
by the NLS and the linear Patlak methods. The correlation
coefficients between the results of Patlak method and those of
the 4-P model and the 5-P model using the NLS method are
97.2% and 94.9%, respectively. The results are not very ideal;
perhaps this is due to certain simplification already discussed
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Fig. 4. Graph shows the generated TACs of the HCC ROI and the nontumor liver tissue ROI with symbol . While, dashed lines are the results of the fitted TACs
using 5-P model; dotted lines are the results of the fitted TACs using 4-P model.
TABLE III
RESULTS OF ESTIMATION OF THE LHMRAct FOR THE 4-P AND 5-P MODELS WITH DUAL INPUTS USING THE NLS AND PATLAK METHODS
before. Other limitations include a moderate amount of noise
scatters intrinsically found in all dynamic PET sampling pro-
tocols, as well as a high degree of freedom (21), potentially
leading to fitting difficulties. From compartment analysis using
the NLS algorithms for 4-P model, the following physiolog-
ical parameters are obtained. For nontumor liver tissue, the
mean value of is 0.661 ml/min/ml; is 0.310/min; is
0.088 /min. The estimated forward clearance K (LHMRAct)
by the NLS and Patlak methods are ml/min/ml
and ml/min/ml, respectively. For the two ROIs
of HCC, the estimated LHMRAct by the NLS methods are
0.2883 ml/min/ml and 0.4743 ml/min/ml and by the Patlak
method are 0.2644 ml/min/ml and 0.4682 ml/min/ml, respec-
tively. The LHMRAct of the non-FDG-avid type of HCC
(regions 9 and 12) are significantly higher than those of the
nontumor liver parenchyma . Although among the
twelve datasets there are only two suffering from HCC, the func-
tional parameters of C-acetate in this tumor have shown sta-
tistically significant difference. Therefore, parametric imaging
with C-acetate metabolism measured quantitatively (LHM-
RAct) may add supportive evidence of the usefulness of this
tracer to tumor detection.
In summary, this three-compartment 4-P model with dual
input functions has been found suitable in mapping the kinetic
characters of C-acetate in a 10-min dynamic PET imaging
of the liver. The model has provided a better understanding
of the complexity and biochemistry of the behavior of this
tracer in HCC and nontumor liver tissue. A 10-min dynamic
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acquisition of C-acetate PET imaging may provide enough
valuable quantitative data. These findings suggest that the
LHMRAct could be considered as potential indicators of
metabolism (other than SUV) for evaluating HCC. C-acetate
is a complementary tracer and perhaps a better tracer than FDG
for detection of HCC.
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